Gilead challenges Government over patents on preventative HIV drug Truvada
August 22, 2019Research and Development, Sales and Marketing AIDS, CDC, Gilead, HIV, IP, PrEP, Truvada, government, patents
Gilead is challenging the US Government’s patents on PrEP drug Truvada. The Foster City firm has submitted a challenge to …
GSK’s two drug HIV regimen effective when administered every two months
August 22, 2019Research and Development AIDS, GSK, HIV, ViiV Healthcare, viral supression
GSK’s long-acting, two-drug HIV regimen was as effective in supressing patient’s viral loads when administered every two months (eight weeks), …
NHS patients to receive AbbVie’s Skyrizi for plaque psoriasis following NICE recommendation
August 21, 2019Research and Development, Sales and Marketing AbbVie, NICE, Skyrizi, pharma
AbbVie’s Skyrizi (risankizumab) has been awarded a positive recommendation from UK drug watchdog NICE, meaning that the IL-23 inhibitor will …
Teva launch generic version of EpiPen for children
August 21, 2019Research and Development Mylan, Teva, allergies, children, epipen, pharma
A generic version of Mylan’s EpiPen, manufactured by Teva, is now available for children weighing between 15kg and 30kg in …
AstraZeneca’s Imfinzi flops in advanced treatment-naive non-small cell lung cancer
August 21, 2019Research and Development AstraZeneca, Cancer, Imfinzi, lung cancer, pharma
New data have emerged illustrating that AstraZeneca’s anti-CTLA4 antibody Imfinzi (durvalumab) failed to meet its primary endpoint when used in …
NHS England to fund Hemlibra for patients with severe haemophilia
August 21, 2019Research and Development Chugai, Hemlibra, Roche, haemophilia, pharma
NHS England is to fund Roche and Chugai Pharma UK’s haemophilia drug Hemlibra, for people with sever congenital haemophilia A …
Novartis exec pushed out over Zolgensma data scandal denies wrongdoing
August 21, 2019Research and Development AveXis, FDA, Novartis, Zolgensma, data scandal, pharma, sma
Dr Brian Kaspar, the Novartis exec pushed out of AveXis over the Zolgensma data scandal, has said in a statement …
AstraZeneca’s Farxiga meets Phase 3 primary endpoint in heart failure
August 20, 2019Manufacturing and Production, Sales and Marketing AstraZeneca, cardiovascular disease, farxiga
New Phase 3 data has been unveiled for AstraZeneca’s Farxiga (dapagliflozin), confirming that the SGLT2 inhibitor met its primary composite …
California man gets eight years in prison for falsely labelling erectile dysfunction drug
August 20, 2019Manufacturing and Production FDA, erectile dysfunction, labellnig, pharma, tadalafil
A man from Walnut, California has been sentenced to eight years and four months in federal prison for illegally importing …
FDA turns down Sarepta’s DMD drug over safety concerns
August 20, 2019Manufacturing and Production DMD, FDA, approval safety, pharma, sarepta
The FDA has declined to approve Sarepta Therapeutics’ Duchenne muscular dystrophy (DMD) drug, citing safety concerns including risk of infection …
FDA greenlights Nebriva’s Xenleta for community-acquired bacterial pneumonia
August 20, 2019Manufacturing and Production, Sales and Marketing FDA, Nabriva, US, Xenleta, pharma, pneumonia
The FDA has awarded approval in the US to Nebriva Therapeutics’ Xenleta (lefamulin) for the treatment of adult patients with …
Drop in prescriptions for antibiotic leads to fewer cases of superbug in Wales
August 20, 2019Manufacturing and Production AMR, Antibiotics, C difficile, C. difficile, pharma, superbug
Cuts to the number of prescriptions for antibiotics have led to a drop in the number of cases of the …
Finding the needle in the haystack of rare disease
August 19, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, Genomenon, Rare Genomics Institute, pharma, rare disease
Through the use of Genomenon’s AI-driven Mastermind Genomic Search Engine, the Rare Genomics Institute succeeded where a leading genetics laboratory …
Celgene’s Inrebic becomes second FDA-approved therapy for rare bone marrow disorder
August 19, 2019Sales and Marketing Cancer, Cerlgene, FDA, Inrebic, pharma, rare disease
Celgene is celebrating the approval in the US of its Janus kinase (JAK) 2 inhibitor Inrebic (fedratinib) in the treatment …
British and American healthcare professionals predict further delays to Brexit as Europeans expect no-deal
August 19, 2019Sales and Marketing EU, UK, US, brexit, brexit delay, healthcare, no-deal, pharma
The majority of healthcare professionals in Europe, Britain and America think Brexit will happen. However they do not believe that …
AbbVie scoops up FDA approval for Rinvoq in moderately to severely active rheumatoid arthritis
August 19, 2019Sales and Marketing AbbVie, FDA, Rinvoq, pharma, rheumatoid arthritis
The FDA has awarded marketing authorisation to AbbVie’s Rinvoq (upadacitinib) for the treatment of moderately to severely active rheumatoid arthritis, …
UK Government calls on social media companies to fight misinformation surrounding vaccines
August 19, 2019Sales and Marketing MMR, anti-vaxxers, measles, pharma, vaccination, vaccines
Boris Johnson has called on social media companies to come together to discuss ways in which they can promote accurate …
Novartis exec sold off shares before Zolgensma data scandal was revealed
August 19, 2019Sales and Marketing AveXis, Novartis, Shares, Zolgensma, pharma, stock market
An unnamed Novartis executive sold 925,400 Swiss francs (£778,665) worth of shares in the firm just weeks before the FDA …
Roche’s cancer drug Rozlytrek scores double approval from FDA
August 16, 2019Medical Communications Cancer, Roche, Rozlytrek, lung cancer, oncology
The FDA has approved Roche’s Rozlytrek (entrectinib) as a treatment for adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC). …
Hundreds of patients turn to private cannabis clinics in UK
August 16, 2019Medical Communications Marijuana, NHS, UK, cannabis, medicinal cannabis, pharma
Hundreds of people have turned to private clinics, in an effort to gain access to medicinal cannabis in the UK, …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
